$DRMA Balance Sheet | Understand Stock

$DRMA

$0.87 +$0.12 (15.85%) Close

$DRMA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Cash and cash equivalents
Cash and cash equivalents
Prepaid expenses and other current assets
Inventories
Total current assets
Property and equipment
Other assets
Total assets
Liabilities and Stockholders’ Equity:
Liabilities:
Accounts payable (including related party amounts of $137,491 and $86,250, respectively)
Accrued and other current liabilities
Convertible subordinated promissory notes, net of discount
Related party convertible subordinated promissory notes, net of discount
Current portion of long-term debt, net of debt discount
Accrued and other current liabilities (including related party amounts of $0 and $25,000, respectively)
Total liabilities

Stockholders’ Equity:
Preferred Stock, par value $0.0001 per share, 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2025 and December 31, 2024
Common Stock, par value $0.0001, 250,000,000 shares authorized; 4,022,143 shares issued and outstanding as of June 30, 2026; 2,660,110 shares issued and outstanding as of December 31, 2025.
Class A Common
Class A Common
Class B Common
Class B Common
Total common Stock, par value $0.0001, 250,000,000 shares authorized; 4,022,143 shares issued and outstanding as of June 30, 2026; 2,660,110 shares issued and outstanding as of December 31, 2025.

Additional paid-in capital
Accumulated deficit
Class A Common
Class A Common
Class B Common
Class B Common
Total stockholders’ equity

Total liabilities and stockholders’ equity

Comments